SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) Files An 8-K Submission of Matters to a Vote of Security Holders

SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07. Submission of Matters to a Vote of Security Holders.

On November 23, 2016, Semler Scientific, Inc. (the
Company) held its Annual Meeting of the Stockholders (the
Annual Meeting) at the offices of Cooley LLP, 101
California Street, Floor 5, San Francisco, California 94111. At
the Annual Meeting, the Companys stockholders voted on two
proposals, each of which is described in more detail in the
Companys definitive proxy statement on Schedule 14A filed with
the U.S. Securities and Exchange Commission on October 21, 2016.
The following is a brief description of each matter voted upon
and the certified results, including the number of votes cast for
and against each matter and, if applicable, the number of
abstentions and broker non-votes with respect to each matter.

Proposal 1. Stockholders elected each of the
following nominees to serve as Class I Directors on the Companys
board of directors (the Board) until the Companys 2019
Annual Meeting of Stockholders or until his respective successor
has been duly elected and qualified. The voting results for each
of the nominees were as follows:

Director Name Votes For Votes Against Votes Withheld Broker Non- Votes Percentage of Votes in Favor
Arthur Abbie Leibowtiz, M.D., F.A.A.P. 2,899,441 217,476 981,263 93.02 %
Wayne T. Pan, M.D., Ph.D. 2,890,466 9,175 217,476 981,263 92.73 %

Proposal 2. Stockholders ratified the selection
by the Audit Committee of the Board of BDO USA, LLP as the
Companys independent registered public accounting firm for the
year ending December 31, 2016. The voting results were as

Votes For Votes Against Abstentions Percentage of Votes in Favor
4,098,301 100.00 %


Semler Scientific, Inc. develops, manufactures and markets products and services that assist healthcare insurers and physician groups in evaluating and treating chronic diseases. The Company markets QuantaFlo and WellChec to its customers. QuantaFlo is an approximately four-minute in-office blood flow test. The routine office usage of the QuantaFlo has ranges from few tests per week to over 10 tests per day. The Company also offers contracts in which it invoices on a per test basis for use of QuantaFlo, or as part of the WellChec multi-test platform. WellChec is the Company’s multi-test service platform. WellChec provides testing equipment and third-party personnel to perform tests and examinations of patients for the Company’s customers. The tests performed are for chronic disease states, which include respiratory disease, vascular disease, eye disease, bone disease, heart disease, neuropathy and diabetes.


SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) closed its last trading session 00.00 at 1.70 with 137,213 shares trading hands.

An ad to help with our costs